Clinical implementation of circulating tumour DNA testing for EGFR T790M for detection of treatment resistance in non-small cell lung cancer

AIMS: Epidermal growth factor receptor (EGFR) T790M mutations can be detected in the circulating tumour DNA from plasma of patients with non-small cell lung cancer (NSCLC) to triage patients for osimertinib eligibility and monitor patients longitudinally for development of T790M-mediated resistance....

Descripción completa

Detalles Bibliográficos
Autores principales: Spence, Tara, Perera, Sheron, Weiss, Jessica, Grenier, Sylvie, Ranich, Laura, Shepherd, Frances, Stockley, Tracy L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7841482/
https://www.ncbi.nlm.nih.gov/pubmed/32471890
http://dx.doi.org/10.1136/jclinpath-2020-206668

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7841482/
https://www.ncbi.nlm.nih.gov/pubmed/32471890
http://dx.doi.org/10.1136/jclinpath-2020-206668

Ejemplares similares